Wales advised not to prescribe PrEP to prevent HIV transmission
Wales advised not to prescribe PrEP to prevent HIV transmission
- NHS England is currently conducting a trial of the medication which it plans to extend to 10,000 participants over the coming months.
However, the All Wales Medicines Strategy Group (AWMSG) today announced that it does not recommend PrEP for use on the NHS in Wales. It has indicated that it is not convinced of the drug’s cost efficiency.
PrEP is manufactured under the brand name Truvada. It may cost up to £400 per patient a month, although the NHS may be able to negotiate a discount for bulk orders.
The decision is a recommendation only and the Welsh Government could act against it. However, campaigners for PrEP provision – which has been credited with driving down HIV transmission rates among gay men in other parts of the UK – reacted with disappointment.
- NHS England is currently conducting a trial of the medication which it plans to extend to 10,000 participants over the coming months.
However, the All Wales Medicines Strategy Group (AWMSG) today announced that it does not recommend PrEP for use on the NHS in Wales. It has indicated that it is not convinced of the drug’s cost efficiency.
PrEP is manufactured under the brand name Truvada. It may cost up to £400 per patient a month, although the NHS may be able to negotiate a discount for bulk orders.
The decision is a recommendation only and the Welsh Government could act against it. However, campaigners for PrEP provision – which has been credited with driving down HIV transmission rates among gay men in other parts of the UK – reacted with disappointment.